Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16489
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRummel, M-
dc.contributor.authorKim, TM-
dc.contributor.authorAversa, F-
dc.contributor.authorBrugger, W-
dc.contributor.authorCapochiani, E-
dc.contributor.authorPlenteda, C-
dc.contributor.authorRe, F-
dc.contributor.authorTrask, P-
dc.contributor.authorOsborne, S-
dc.contributor.authorSmith, R-
dc.contributor.authorGrigg, Andrew P-
dc.date2016-12-28-
dc.date.accessioned2017-01-09T04:26:03Z-
dc.date.available2017-01-09T04:26:03Z-
dc.date.issued2016-12-28-
dc.identifier.citationAnnals of Oncology 2016; online first: 28 Decemberen_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16489-
dc.description.abstractBACKGROUND: To evaluate patient preference and satisfaction for the subcutaneous (SC) versus intravenous (IV) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). PATIENTS AND METHODS: Patients received 8 cycles of rituximab according to 2 schedules: Arm A received 1 cycle rituximab IV (375 mg/m2) and 3 cycles rituximab SC (1400 mg) then 4 cycles rituximab IV; Arm B received 4 cycles rituximab IV (375 mg/m2) then 4 cycles rituximab SC (1400 mg). Alongside rituximab, both arms received 6-8 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP], cyclophosphamide, vincristine, prednisone [CVP], or bendamustine as per standard local practice). Preference for SC or IV administration was evaluated using the Patient Preference Questionnaire (PPQ) at cycles 6 and 8. Patient satisfaction and convenience were assessed using the Cancer Therapy Satisfaction Questionnaire (CTSQ), and Rituximab Administration Satisfaction Questionnaire (RASQ) at cycles 4 and 8. RESULTS: At the primary data cut-off (19 January 2015), the intent-to-treat population comprised 743 patients. The majority had DLBCL (63%) and baseline characteristics were balanced between arms. At cycle 8, 81% of patients completing the PPQ preferred rituximab SC. Preference was not impacted by treatment sequence or disease type. Patient satisfaction as measured by RASQ was higher for SC versus IV. CTSQ scores were similar between arms. Adverse events were generally balanced between administration routes and no new safety signals were detected. CONCLUSION: Most previously untreated patients with CD20+ DLBCL or FL preferred SC to IV rituximab administration. Patient satisfaction with rituximab treatment was generally greater with SC administration.en_US
dc.subjectRituximaben_US
dc.subjectChemotherapyen_US
dc.subjectSubcutaneousen_US
dc.subjectDLBCLen_US
dc.subjectFLen_US
dc.titlePreference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAnnals of Oncologyen_US
dc.identifier.affiliationDepartment of Hematology & Oncology, University Hospital Giessen and Marburg, Giessen, Germanyen_US
dc.identifier.affiliationDivision of Hematology & Medical Oncology, Seoul National University Hospital, Seoul, South Koreaen_US
dc.identifier.affiliationUniversity of Parma, Parma, Italyen_US
dc.identifier.affiliationSchwarzwald-Baar Clinic Villingen-Schwenningen, Academic Teaching Hospital, University of Freiburg, Germanyen_US
dc.identifier.affiliationCenter for Hematology, Livorno, Italyen_US
dc.identifier.affiliationUniversity Hospital Parma, Parma, Italyen_US
dc.identifier.affiliationGenentech, Inc., South San Francisco, USAen_US
dc.identifier.affiliationF. Hoffmann-La Roche Ltd, Basel, Switzerlanden_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28031173en_US
dc.identifier.doi10.1093/annonc/mdw685en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherGrigg, Andrew P
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.